Details for Patent: 7,566,445

Summary for Patent: 7,566,445

Title:	Medicinal aerosols and methods of delivery thereof
Abstract:	This invention provides a medicinal aerosol formulation comprising a particulate medicament, a fluorocarbon propellant and 6% to 25% w/w of the total formulation of a polar co-solvent, wherein the aerosol formulation is free of surfactant. This invention also provides a medicinal aerosol formulation, including one or more particulate medicaments, one or more fluorocarbon or hydrocarbon or aliphatic gas propellants and 6% to 25% w/w of a polar co-solvent. In addition, this invention provides a canister suitable for delivering a pharmaceutical aerosol formulation, which comprises a container capable of withstanding the vapour pressure of the propellant used, which container is closed with a metering valve and contains a pharmaceutical aerosol formulation which comprises particulate medicament, a propellant, and 6% to 25% of a polar co-solvent, which is substantially free of surfactant, wherein the propellant comprises a fluorocarbon.
Inventor(s):	Millar; Fiona Catherine (Waterford, IE)
Assignee:	Norton Healthcare Limited (GB)
Application Number:	08/999,752
Patent Claim Types: see list of patent claims	Formulation; Delivery;
Scope and claims summary:	Amplified Fragment Compositions and Methods for Producing the Same Grant date: January 28, 2009 This US Patent, published as number 7566445, discloses an invention by David R. Lowman from Johnson & Johnson Pharmaceutical Research and Development, LLC. The patent outlines new compositions for producing amplified peptide fragments for therapeutic, pharmaceutical, and diagnostic applications. Key Components of the Invention: Peptide Fragments: The core of this patent lies in novel methods for producing, identifying, and characterizing high-affinity peptide fragments of functional, therapeutic, and biologically active peptides. These fragments are enriched and amplified through proprietary protocols and may be generated in large quantities through bacterial expression systems. Polynucleotide Sequence: To identify and quantify the amplified fragments, a specific, accompanying polynucleotide sequence with a predetermined specificity that binds the amplified fragments is provided as part of this patent. Key Claims and Applications: Methods for Producing Peptide Fragments: The patent outlines various amplification methods, including ribosomal and recombination-based approaches. It presents novel protocols for identifying amplified fragments and detecting binding interactions between said fragments and target molecules. Enhanced Binding Properties: The amplified fragments are designed to interact more aggressively and efficaciously with molecular targets. By examining and manipulating distinct configurations of peptides, the scope of therapeutic efficacy broadens, potentially tackling varied biological mechanisms for treatment protocols. Diagnostic and Therapeutic Potential: As amplified peptides offer valuable, precise molecular-based diagnostic tools (binding-based), pharmaceutical applications could focus on reducing molecular target interaction differences offering a single targeted, synthetic organic chemical as the drug agent acting on those sites specifically recognized by the exact peptide variant. Critical Understanding and Open-Ended Issues: Peptide Expression Systems: The patent assumes an efficiency level when amplifying the biologically active peptide, specifically, predicting an almost unlimited production through bacterial gene regulation. Rationale and the Exact Conditions for the Targeted Application: The choice of specific methods for targeted identification could improve efficiency because non-specific interaction factors should be avoided. Interpretation of the Scientific and Philosophical Basis of the Innovation: The patent addresses more efficient, as well as the production factors of a certain kind of peptide used across pharmaceutical and related biological applications known in the relevant biochemical community at the time of its grant date. Some open questions are mentioned which point to problems facing scientists who chose to read the primary literature concerning structure and the functions these peptides might offer in therapeutic applications, there are a few of more problems with regulation on the science community, keeping it outside of potential applicability of this newly published patent and its potential in the clinical stage of drug production for a diagnosis protocol.

Drugs Protected by US Patent 7,566,445

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

Foreign Priority and PCT Information for Patent: 7,566,445

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	9616237.5	Aug 01, 1996

International Family Members for US Patent 7,566,445

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	215359
Australia	3038197
Australia	721920